Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
|Videos|December 2, 2016
WATCH: WHO Guide to Testing Options for HIV
In this week's "Around the Web," Pharmacy Times presents a video that was recently posted by the World Health Organization, which discusses self-testing options for HIV.
Advertisement
In this week's "Around the Web," Pharmacy Times presents a video that was recently posted by the World Health Organization, which discusses self-testing options for HIV.
Cheryl Johnson, HIV Testing Specialist, explains how the new WHO guidance will support countries to promote self-testing and increase access to HIV.
Advertisement
Related to this article
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5